Relevance of Molecular Markers in Prostate Cancer
Authors: John Concato
Journal: Annals of Internal Medicine (2009)

Letters15 December 2009Relevance of Molecular Markers in Prostate CancerJohn Concato, MD, MPH, Edward Uchio, MD, and Carolyn K. Wells, MPHJohn Concato, MD, MPHFrom Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.Search for more papers by this author, Edward Uchio, MDFrom Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.Search for more papers by this author, and Carolyn K. Wells, MPHFrom Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-12-200912150-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The editorial by Gelmann and Henshall (1) on our article (2) regarding molecular markers in prostate cancer (2) may generate several misconceptions. Our emphasis was on novel associations between molecular markers obtained at biopsy and long-term mortality. Although many articles “evaluating correlations of P53 and BCL2 expression and microvessel density” (1) have indeed been published elsewhere, a gap in knowledge still existed—whether marker status at diagnosis (vs. after surgery) affects survival (vs. presuming biochemical failure is an equivalent outcome). By conducting a comprehensive review of medical records, retrieving original biopsy tissue, and using rigorous methods of clinical ...References1. Gelmann EP, Henshall SM. Clinically relevant prognostic markers for prostate cancer: the search goes on [Editorial]. Ann Intern Med. 2009;150:647-9. [PMID: 19414846] LinkGoogle Scholar2. Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Ann Intern Med. 2009;150:595-603. [PMID: 19414838] LinkGoogle Scholar3. Kraft P, Hunter DJ. Genetic risk prediction—are we there yet? N Engl J Med. 2009;360:1701-3. [PMID: 19369656] CrossrefMedlineGoogle Scholar4. McKenzie S, Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem. 2006;97:18-32. [PMID: 16216007] CrossrefMedlineGoogle Scholar5. Schlomm T, Erbersdobler A, Mirlacher M, Sauter G. Molecular staging of prostate cancer in the year 2007. World J Urol. 2007;25:19-30. [PMID: 17334767] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: John Concato, MD, MPH; Edward Uchio, MD; Carolyn K. Wells, MPHAffiliations: From Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoClinically Relevant Prognostic Markers for Prostate Cancer: The Search Goes On Edward P. Gelmann and Susan M. Henshall Molecular Markers and Death From Prostate Cancer John Concato , Dhanpat Jain , Edward Uchio , Harvey Risch , William W. Li , and Carolyn K. Wells Relevance of Molecular Markers in Prostate Cancer Edward P. Gelmann and Susan M. Henshall Metrics 15 December 2009Volume 151, Issue 12Page: 894KeywordsBiopsyCancer treatmentClinical epidemiologyConflicts of interestForecastingGeneticsMortalityProstate cancerSurgery ePublished: 15 December 2009 Issue Published: 15 December 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...